EBV-positive immunodeficiency lymphoma after alemtuzumab-CHOP therapy for peripheral T-cell lymphoma.

Abstract	Chemotherapy with alemtuzumab and the combination of cyclophosphamide, adriamycin, oncovin, and prednisone (CHOP) has become experimental trial therapy for aggressive T-cell lymphoma. Several multicenter phase 3 trials will incorporate this scheme. As part of an ongoing phase 2 trial in which we recently treated 20 patients with 8 cycles of CHOP every 2 weeks with 3 additional doses of 30 mg alemtuzumab per cycle, we observed the development of Epstein-Barr virus (EBV)-positive lymphoproliferative disease, after completion of the immunochemotherapy in 3 patients with peripheral T-cell lymphoma. Because the occurrence of EBV-positive lymphoproliferative disease is rare after alemtuzumab monotherapy, such as is given for chronic lymphocytic leukemia, we think that early reporting of this potential side effect is warranted. It may be caused by intrinsic T-cell defects in patients with T-cell lymphoma, or by the combination of alemtuzumab with CHOP chemotherapy.
Authors	Hanneke C Kluin-Nelemans, Jules L Coenen, James E Boers, Gustaaf W van Imhoff, Stefano Rosati
Journal	Blood (Blood) Vol. 112 Issue 4 Pg. 1039-41 (Aug 15 2008) ISSN: 1528-0020 [Electronic] United States
PMID	18502831 (Publication Type: Case Reports, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Antibodies, Neoplasm Alemtuzumab Vincristine Doxorubicin Cyclophosphamide Prednisone
Topics	Adult Alemtuzumab Antibodies, Monoclonal (administration & dosage, adverse effects) Antibodies, Monoclonal, Humanized Antibodies, Neoplasm (administration & dosage, adverse effects) Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use) Cyclophosphamide Doxorubicin Female Herpesvirus 4, Human Humans Immunologic Deficiency Syndromes (chemically induced) Lymphoma (chemically induced, immunology, virology) Lymphoma, T-Cell, Peripheral (drug therapy) Male Middle Aged Prednisone Vincristine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!